Cempra: Binding bacteria better

Using a set of in-licensed macrolide chemistry technologies, Cempra Pharmaceuticals Inc. is developing a pipeline of macrolide antibiotics that it hopes will be effective against resistant bacteria but have safety profiles similar to marketed macrolides. The company began Phase I studies of CEM-101 in healthy volunteers this month.

Macrolides inhibit bacterial protein synthesis by binding reversibly to a peptide tunnel on the 50S subunit of the

Read the full 653 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE